ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,070Medicare Part D Prescriptions Filled, Including Refills

Rank: 137 out of 617

$378K Total Retail Price of All Prescriptions

Rank: 167 out of 617

386 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
38% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

12% of this provider’s 386 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

2% of this provider’s 7,945 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$42 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 558 472 1 1
OMEPRAZOLE 449 399 2 3
WARFARIN SODIUM 298 284 3 7
SIMVASTATIN 277 239 4 2
METFORMIN HCL 237 213 5 9
POLYETHYLENE GLYCOL 3350 212 202 6 32
FUROSEMIDE 211 189 7 4
ENALAPRIL MALEATE 211 204 7 34
AMLODIPINE BESYLATE 191 183 9 6
TRAMADOL HCL 175 145 10 15
POTASSIUM CHLORIDE 174 158 11 10
SERTRALINE HCL 138 120 12 20
LISINOPRIL 137 125 13 5
HYDROCHLOROTHIAZIDE 135 118 14 13
LABETALOL HCL 128 128 15 224
HYDROCODONE-ACETAMINOPHEN 127 104 S3 16 8
CLONIDINE HCL 119 107 17 55
ZOLPIDEM TARTRATE 115 80 18 23
ATENOLOL 112 104 19 17
METOPROLOL SUCCINATE 102 97 20 12
ENALAPRIL-HYDROCHLOROTHIAZIDE 84 82 21 183
ATORVASTATIN CALCIUM 82 73 22 14
CARVEDILOL 81 76 23 19
DIGOXIN 79 79 24 48
TRIAMTERENE-HCTZ 79 79 24 47
MELOXICAM 75 68 26 24
RANITIDINE HCL 74 73 27 40
GABAPENTIN 73 61 28 16
CYCLOBENZAPRINE HCL 72 48 R 29 74
MIRTAZAPINE 71 59 30 50
TAMSULOSIN HCL 71 59 30 26
FLUOXETINE HCL 65 48 32 73
METOPROLOL TARTRATE 63 60 33 11
SINGULAIR 61 53 34 106
CITALOPRAM HBR 58 46 35 18
BYSTOLIC 56 56 36 64
LOSARTAN-HYDROCHLOROTHIAZIDE 56 48 36 46
BISOPROLOL-HYDROCHLOROTHIAZIDE 56 46 36 87
CRESTOR 55 45 39 28
ALENDRONATE SODIUM 55 55 39 25
IMIPRAMINE HCL 54 34 R 41 309
LIPITOR 54 54 41 118
CARBIDOPA-LEVODOPA 54 41 41 69
VENLAFAXINE HCL 53 16 44 223
PREDNISONE 53 49 44 31
LOSARTAN POTASSIUM 52 52 46 22
LOVASTATIN 51 51 47 57
TERAZOSIN HCL 50 50 48 96
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 4, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.